Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(80.0%)
Phase 4
1(20.0%)
5Total
N/A(4)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06606236Not ApplicableCompleted

Neuropeptide Y Regulates Neurogenic Pulp Inflammation

Role: lead

NCT06482593Phase 4Active Not Recruiting

Periapical Healing in Response to Endodontically Treated Teeth With Different Sealing Cement

Role: lead

NCT04881786Not ApplicableCompleted

Calcitonin Gene-related Peptide Expression in Human Periodontal Ligament

Role: lead

NCT03804034Not ApplicableCompleted

Importance of Neurogenic Inflammation in the Angiogenic Response of the Dental Pulp as a Defensive Response

Role: lead

NCT03680534Not ApplicableCompleted

3D Analysis of Root Canal Conformation

Role: lead

All 5 trials loaded